Small molecule inhibitors of IgE synthesis

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 17, 2006, Pages 4697-4699

  Brown, Alan ^a   Henderson, Alan ^b   Lane, Charlotte ^a   Lansdell, Mark ^a   Maw, Graham ^a   Monaghan, Sandy ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b Albany Molecular Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN E ANTIBODY;

ARTICLE; DRUG METABOLISM; DRUG POTENCY; DRUG STABILITY; GENETIC TOXICOLOGY; IMMUNOGLOBULIN PRODUCTION; MOLECULAR SIZE;

CYTOCHROME P-450 CYP1A1; CYTOCHROME P-450 CYP1A2; HUMANS; IMMUNOGLOBULIN E; INHIBITORY CONCENTRATION 50; LEUKOCYTES; MOLECULAR STRUCTURE; MOLECULAR WEIGHT; ORGANIC CHEMICALS;

EID: 33746233437     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.05.042     Document Type: Article

References (21)

1. Sears M.R., Burrows B., Flannery E.M., Herbison G.P., Hewitt C.J., and Holdaway M.D. N. Eng. J. Med. 325 (1991) 1067
2. Burrows B., Martinez F.D., Halonen M., Barbee R.A., and Cline M.G. N. Eng. J. Med. 320 (1989) 271
3. Barbee R.A., and Halonen M. Chest 99 (1991) 20
4. Lane S.J., and Kemeny D.M. Clin. Exp. Allergy 24 (1994) 1001
5. Dombrowicz D., Flamand V., Brigmann K.K., Koller B.H., and Kinet J.P. Cell 75 (1993) 969
6. Oba Y., and Salzman G.A. J. Allergy Clin. Immunol. 114 (2004) 265
7. Representative examples include:. Berger M., Albrecht B., Berces A., Ettmayer P., Neruda W., and Woisetschlaeger M. J. Med. Chem. 44 (2001) 3031
8. Hasegawa M., Takenouchi K., Takahashi K., Takeuchi T., Komoriya K., Uejima Y., and Kamimura T. J. Med. Chem. 40 (1997) 395
9. 50 values were calculated and data normalized to an internal standard to take into account donor to donor variability. The cytotoxicity of compounds was also evaluated and shown to be unrelated to efficacy. For selected compounds, compound concentration was evaluated during the course of the experiment and was shown to remain unchanged.
10. Compounds (1 μM) were incubated at 37 °C with human liver microsomes (0.5 μM) for 60 min. Concentration of compound was measured over the time course of the experiment and used to determine a disappearance half-life.
11. Compounds (1 μM) were incubated at 37 °C with recombinant CYP1A1 or CYP1A2 (0.15 μM) for 60 min. Concentration of compound was measured over the time course of the experiment and used to determine a disappearance half-life.
12. CYP1A1 is predominantly expressed in extra-hepatic tissues. See:. Smith G., Stubbins M.J., Harries L.W., and Wolf C.R. Xenobiotica 28 (1998) 1129
13. Ames B.N., McCann J., and Yamasaki E. Mutat. Res. 31 (1975) 347
14. Ames D.N., and Maron D.M. Mutat. Res. 113 (1983) 173
15. For CYP1A enzymes see, for example:. Lewis D.F.V. Current Med. Chem. 10 (2003) 1955
16. Benigni R. Chem. Rev. 105 (2005) 1767
17. It is likely that the reduced lipophilicity of these compounds also contributes to their increased metabolic stability.
18. 2O requires C, 52.15; H, 6.71; N, 22.81%.
19. Bonnet P.A., Michel A., Laurent F., Sablayrolles C., Rechencq E., Mani J.C., Boucard M., and Chapat J.P. J. Med. Chem. 35 (1992) 3353
20. Sato N. J. Heterocycl. Chem. 17 (1980) 143
21. Despite extensive experimentation we were unable to ascertain the specific mechanism of action for these compounds.